Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M26,739Revenue $M1,212Net Margin (%)-56.9Z-Score13.7
Enterprise Value $M26,038EPS $-2.0Operating Margin %-97.1F-Score2
P/E(ttm))0Cash Flow Per Share $-0.3Pre-tax Margin (%)-103.7Higher ROA y-yN
Price/Book22.910-y EBITDA Growth Rate %0Quick Ratio3.7Cash flow > EarningsY
Price/Sales31.45-y EBITDA Growth Rate %0Current Ratio3.7Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-20.0Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-37.2Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M236ROI % (ttm)-31.5Gross Margin Increase y-yY

Gurus Latest Trades with VRTX

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VRTXJohn Burbank 2014-06-30 Sold Out -0.01%$62.44 - $93.77
($69.73)
$ 113.5863%Sold Out0
VRTXGeorge Soros 2014-06-30 Sold Out -0.01%$62.44 - $93.77
($69.73)
$ 113.5863%Sold Out0
VRTXVanguard Health Care Fund 2014-03-31 Add0.13%$67.8 - $85.48
($79.08)
$ 113.5844%Add 5.89%11,628,500
VRTXGeorge Soros 2014-03-31 Buy 0.01%$67.8 - $85.48
($79.17)
$ 113.5844%New holding, 10000 sh.10,000
VRTXJohn Burbank 2014-03-31 Buy 0.01%$67.8 - $85.48
($79.17)
$ 113.5844%New holding, 2872 sh.2,872
VRTXVanguard Health Care Fund 2013-12-31 Add0.88%$60.18 - $77.83
($69.45)
$ 113.5864%Add 54.06%10,981,500
VRTXVanguard Health Care Fund 2013-09-30 Add0.29%$74.53 - $88.51
($79.62)
$ 113.5843%Add 19%7,127,997
VRTXVanguard Health Care Fund 2013-06-30 Add1.05%$52.6 - $85.6
($73.64)
$ 113.5854%Add 140.58%5,990,000
VRTXDaniel Loeb 2012-12-31 Sold Out -0.77%$38.88 - $59.42
($46.08)
$ 113.58146%Sold Out0
VRTXJohn Burbank 2012-12-31 Sold Out -0.38%$38.88 - $59.42
($46.08)
$ 113.58146%Sold Out0
VRTXDaniel Loeb 2012-09-30 Add0.22%$48.38 - $59.07
($53.5)
$ 113.58112%Add 40%700,000
VRTXJohn Burbank 2012-09-30 Reduce-0.09%$48.38 - $59.07
($53.5)
$ 113.58112%Reduce -25%150,000
VRTXGeorge Soros 2012-09-30 Sold Out -0.09%$48.38 - $59.07
($53.5)
$ 113.58112%Sold Out0
VRTXJoel Greenblatt 2012-09-30 Sold Out -0.08%$48.38 - $59.07
($53.5)
$ 113.58112%Sold Out0
VRTXDaniel Loeb 2012-06-30 Buy 0.85%$35.75 - $65.62
($50.92)
$ 113.58123%New holding, 500000 sh.500,000
VRTXJohn Burbank 2012-06-30 Buy 0.38%$35.75 - $65.62
($50.92)
$ 113.58123%New holding, 200000 sh.200,000
VRTXJoel Greenblatt 2012-06-30 Buy 0.08%$35.75 - $65.62
($50.92)
$ 113.58123%New holding, 20025 sh.20,025
VRTXJohn Hussman 2012-06-30 Sold Out -0.93%$35.75 - $65.62
($50.92)
$ 113.58123%Sold Out0
VRTXGeorge Soros 2012-06-30 Reduce-0.05%$35.75 - $65.62
($50.92)
$ 113.58123%Reduce -44%112,000
VRTXJean-Marie Eveillard 2012-06-30 Sold Out -0.02%$35.75 - $65.62
($50.92)
$ 113.58123%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VRTX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
VRTX Vanguard Health Care Fund 2014-06-3011,807,50052.9+1.54%
VRTX John Burbank 2014-06-30000Sold Out
VRTX George Soros 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


VRTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ALTSHULER DAVIDDirector 2014-09-29Sell2,500$114.75-1.02view
ALTSHULER DAVIDDirector 2014-09-24Sell2,500$109.753.49view
BOGER JOSHUA SDirector 2014-09-24Sell5,200$109.214view
Silva Paul MSVP & Corp Controller 2014-09-19Sell25,408$99.8513.75view
ALTSHULER DAVIDDirector 2014-09-19Sell5,000$102.2511.08view
Arbuckle Stuart AEVP\Chief Commercial Officer 2014-09-19Sell55,521$10013.58view
BOGER JOSHUA SDirector 2014-09-17Sell5,200$93.6221.32view
BOGER JOSHUA SDirector 2014-09-10Sell5,200$94.4220.29view
ALTSHULER DAVIDDirector 2014-09-05Sell2,500$94.7519.87view
BOGER JOSHUA SDirector 2014-09-03Sell5,200$92.7922.41view

Press Releases about VRTX :

    Quarterly/Annual Reports about VRTX:

    News about VRTX:

    Articles On GuruFocus.com
    Vanguard Health Care Fund Buys Vertex Pharmaceuticals, Zoetis Inc, , Sells Cerner Corporation, AbbVi Aug 02 2013 
    Weekly Guru Bargains Highlights: MBI, VRTX, GRPN, PBI, PC Dec 16 2012 
    WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 21 2012 
    Idenix Pharmaceuticals Lagging Behind in Breakthrough Hepatitis C Drug Development Jul 13 2012 
    Weekly Top Insider Sells: GMCR, VRTX, CERN, and AGN May 14 2012 
    Vertex Could Climb On New Drug, VX-222 Success Apr 21 2012 
    Achillion Will Surge If New Drug Is Successful Apr 21 2012 
    Columbia Management Fourth Quarter Letter with Comments on SWK, AGCO, CE, MCP, VRTX, DOLE, F, HAS, A Apr 10 2012 
    Was Gilead's Acquisition of Pharmasset a Dose of Bad Medicine? Mar 05 2012 
    4 Pharmaceuticals with Long and Short Opportunities Feb 28 2012 


    More From Other Websites
    Johnson & Johnson Bets $1.75 Billion On Alios Buy Sep 30 2014
    [video] Q4 momentum Sep 30 2014
    Q4 momentum Sep 30 2014
    Today's Market Thorns, Roses, and All Time Highs... Sep 29 2014
    Today's Market Thorns, Roses, and All Time Highs... Sep 26 2014
    3 Drugs Stocks Driving The Industry Higher Sep 26 2014
    Biotech Stock Mailbag: ProQR, Vertex Pharma, Tekmira, Agios Sep 26 2014
    [video] Fast Money Final Trade: PFE, DOW, VRTX & the dollar Sep 25 2014
    Fast Money Final Trade: PFE, DOW, VRTX & the dollar Sep 25 2014
    Today's Market Thorns, Roses, and All Time Highs... Plus an Extra... Sep 25 2014
    [video] Biotech selloff: What to buy Sep 25 2014
    Biotech selloff: What to buy Sep 25 2014
    Tech swoon: Apple leads decline Sep 25 2014
    Today's Market Thorns, Roses, and All Time Highs... Sep 24 2014
    US STOCKS-Wall St rallies, S&P back above 14-day moving average Sep 24 2014
    US STOCKS-Wall St rallies, S&P back above 14-day moving average Sep 24 2014
    Stocks End Skid; Vertex, Alexion Lead Biotech Rebound Sep 24 2014
    Bed Bath, Starz gain; Citizens Financial debuts Sep 24 2014
    Bed, Bath & Beyond surges Sep 24 2014
    [video] Bed, Bath & Beyond surges Sep 24 2014
    Biotech Stock Roundup: Auxilium an Acquisition Target, Amgen Submits another BLA Sep 24 2014
    3 Stocks Pushing The Drugs Industry Higher Sep 22 2014
    Vertex Pharmaceuticals (VRTX) Jumps: Stock Rises 6.6% Sep 22 2014
    US STOCKS-Biotech shares drop, Amarin plunges 20 pct Sep 12 2014
    US STOCKS-S&P 500 rebounds with energy shares; Dow dips Sep 11 2014
    US STOCKS-Wall St down slightly, financials help limit losses Sep 11 2014
    Vertex Pharma posts bigger 2Q loss Jul 29 2014
    Vertex Receives European CHMP Positive Opinion for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating... Jun 27 2014
    Ahead of the Bell: Vertex soars on study Jun 24 2014
    Vertex ends hepatitis C investment as sales fall May 01 2014
    Gilead profit triples, hepatitis C drug sales beat by $1 billion Apr 22 2014
    Vertex to Present at the Barclays Global Healthcare Conference on March 11 Mar 06 2014
    Vertex to Present at the RBC Global Healthcare Conference on February 25 Feb 20 2014
    Vertex Pharma rises despite lower Incivek sales Jan 30 2014
    Vertex posts profit on royalty deal for hep C drug Jan 29 2014
    Vertex Reviews Corporate Strategy and Outlines Key 2014 Business Priorities at the 32nd Annual J.P.... Jan 12 2014
    Vertex Announces Appointment of Jeffrey A. Chodakewitz, M.D., as Chief Medical Officer and Senior... Jan 08 2014
    Vertex Announces Upcoming Presentation at J.P. Morgan Healthcare Conference and Date of Fourth... Jan 07 2014
    Vertex Announces Results of Phase 3 Study of Ivacaftor in People with CF who have the R117H Mutation Dec 19 2013
    Vertex Sells INCIVO ® Product Royalty Rights for $152 Million Nov 20 2013
    Vertex To Present at Upcoming Investor Conferences Nov 11 2013

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK